faculty of science prof geoff currie, bpharm, mmedradsc, mappmngt, mba, phd faculty of science,...

71
FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health Sciences, Macquarie University Rural Clinical School, University of NSW Peptides Imaging and Therapy May 28 – 30, 2015, Montréal, Québec

Upload: lynette-wilkins

Post on 25-Dec-2015

216 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD

Faculty of Science, Charles Sturt University

Faculty of Medicine and Health Sciences, Macquarie University

Rural Clinical School, University of NSW

Peptides Imaging and Therapy

May 28 – 30, 2015, Montréal, Québec

Page 2: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Educational Objectives

Upon completion of this activity, the participant will be able to:1. Discuss amino acids, peptides, and proteins in medicine.2. Describe the appropriate radiolabeling principles, including radionuclide selection (SPECT, PET, and therapy).3. Describe the radiolabeling methods.4. Apply knowledge to prototype model.

Page 3: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Disclosure Statement: No Conflict of Interest

May 28 – 30, 2015, Montréal, Québec

I do not have an affiliation, financial or otherwise, with a pharmaceutical company, medical device or communications organization.

I have no conflicts of interest to disclose ( i.e. no industry funding received or other commercial relationships).

I have no financial relationship or advisory role with pharmaceutical or device-making companies, or CME provider.

I will not discuss or describe in my presentation at the meeting the investigational or unlabeled ("off-label") use of a medical device, product, or pharmaceutical that is classified by Health Canada as investigational for the intended use.

Page 4: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

.1.Discuss amino acids, peptides, and proteins

in medicine.

Page 5: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Amino Acids

• About 300 amino acids present in various animals, plants, and microbial systems

• Only 20 amino acids are coded by DNA to appear in proteins.

• Cells produce proteins with different properties and activities by joining the 20 amino acids in many different combinations and sequences.

• The properties of proteins are determined by the physical and chemical properties of their monomer units, the amino acids.

Page 6: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Basic Structure of Amino Acids

• Amino acids are the basic structural units of proteins consisting of • an amino group, (-NH2)

• A carboxyl group (-COOH)

• a hydrogen atom (-H) and

• a (variable) distinctive (R) group.

• All of the substituents in amino acid are attached (bonded) to a central α carbon atom.

• This carbon atom is called α because it is bonded to the carboxyl (acidic) group.

Page 7: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Basic Amino Acid Structure

Page 8: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Basic Amino Acid Structure

D (+) amino acid L (-) amino acid

Page 9: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

• Peptide bonds are formed via a condensation reaction forming peptides and proteins out of chains of amino acids; polymerisation.

• Peptides tend to be small comprising just a few amino acids (eg. some hormones and neurotransmitters).

• Proteins are polypeptides and vary in the number of peptides and their configuration.

Page 10: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

• Peptide bonds are covalent bonds.• An amide linkage between carboxyl group of one

amino acid and the amino group of another.• Peptide bonds are resistant to conditions that

normal denature proteins.• Peptide bonds can be broken in high acidic or

basic conditions at elevated temperatures.

Page 11: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

Page 12: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

Page 13: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

Page 14: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Peptide Bonds

Page 15: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Proteins

• Proteins can be large molecules ranging from less than 50 amino acids to more than 10000 with complex shape and structure.

• While peptide bonds tend to suggest a linear structure, proteins are folded into a variety of 3 dimensional shapes that determine functionality.

• Protein structure can be thought of in terms of primary, secondary, tertiary and quaternary structures.

Page 16: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Proteins

• Primary structure relates to the protein configuration arising from the amino acid sequence in the polypeptide chain.

• Secondary structure relates to the manner in which the polypeptide chain is folded (hydrogen bonds).

• Tertiary structure relates to the interactions associated with amino acid side chains.

• Quaternary structure relates to interactions between different polypeptide chains within the same protein.

Page 17: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Primary Structure of Proteins

Page 18: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Secondary Structure of Proteins

Page 19: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Tertiary Structure of Proteins

Page 20: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Quaternary Structure of Proteins

Page 21: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Cell Surface Receptors• Cell surface receptors are specialised proteins

that take part in communication between the cell and the outside world.

• Extracellular signalling molecules (usually hormones, neurotransmitters, cytokines, growth factors or cell recognition molecules) attach to the receptor, triggering changes in the function of the cell.

• Cell surface receptors can be over-expressed in certain diseases and thus become a target for diagnosis and therapy.

Page 22: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Receptor Concept

Page 23: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Receptor Concept

Page 24: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

.2.Describe the appropriate radiolabeling

principles, including radionuclide selection (SPECT, PET, and therapy).

Page 25: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Anatomy of a Bioconjugate

• Content

Zeglis, et al. Dalton Transactions 2011, 40: 6168-6195.

Page 26: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Anatomy of a Bioconjugate

• Biomolecule• Type (peptide)

• Target (receptor)

• Nuclide (ligand)• PET

• SPECT

• Therapy

• Radiometal

• Radiohalogen

Zeglis, et al. Dalton Transactions 2011, 40: 6168-6195.

• Radiohalogen• Direct Labeling

• Prosthetic

• Radiometal• Chelator

• Conjugation

Page 27: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Zeglis, et al. Dalton Transactions 2011, 40: 6168-6195.

Peptide

Chelator

Linker

Radionuclide

Page 28: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Limitations of Non Metals in PET

• Short half-lives only allow evaluation of short biological processes (minutes to a few hours) using rapid pharmacokinetic profiles.

• Short half-lives and necessity of incorporating the radioisotopes into the core structure of the tracer (rather than in an appended chelator or prosthetic group) necessitate complex syntheses.

• Often requires a on-site cyclotron facility.

Page 29: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Biomolecules• Development in the production, purification, and

radiochemistry of PET tracers of the metals • 64Cu (copper),

• 68Ga (gallium),

• 86Y (yttrium),

• 89Zr (zirconium),

• Half-lives consistent with the biological half-lives.• All 4 form stable chelate complexes suitable for the

radiolabeling of biomacromolecules.• Most important application of PET radiometals is

the development of tracers based on peptides

Page 30: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Biomolecule Labelling Principles• Radiometals.• Radiometal is almost never directly attached to the

biomolecule itself. • Radionuclide is bound to a chelating moiety (e.g.

DOTA). • Chelating moiety is covalently attached to the

biomolecule (linker).• The intent is to alter the biochemical properties as

little as possible.

Page 31: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Biomolecules

• Key (choice) is matching the radioactive half-life to the biological half-life of the biomolecule

Page 32: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Therapeutic Radionuclides

177Lu 6.7 d Beta/gamma (208KeV 11%) 1 mm

Page 33: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Pre Targeting

• Challenge to balance maximizing absolute amount of radionuclide that can be delivered to the tumor and meeting the requirement that the tumor-to-normal organ dose ratios be as high as possible.

• The problem is that large molecules such as antibodies provide the highest tumor accumulation, while smaller molecules such as peptides provide the highest tumor-to-normal organ dose ratios.

Page 34: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Pre Targeting

• 68Ga is an inappropriate choice for labeling fully intact IgG molecules, because it will decay through a number of half-lives before the antibody reaches its fully optimal biodistribution within the body.

• One solution is to use longer lived radiometals 64Cu, 86Y, and 89Zr especially with fully intact mAbs. Increases radiation dose!

• But pre targeting may be the best approach.

Page 35: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Pre Targeting

• Break the treatment strategy into two steps.• The first involving an unlabelled macromolecule

that can biologically take as long as necessary to localise in the target in high concentration.

• Followed later by administration of a radiolabeled small molecule that binds specifically to the protein or peptide.

Page 36: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Pre Targeting

Page 37: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Pre Targeting

111In: Rossin, et al. Angew. Chem. Int. Ed. 2010; 49: 3375-8.64Cu: Zeglis, et al. J. Nucl. Med. 2013; 54: 1-8.18F: Devaraj, et al. PNAS. 2013; 109: 4762-4767.

Page 38: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

.3.Describe the radiolabeling methods.

Page 39: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Radiolabelling Methods

• Two processes need to be considered.• The first is the labelling of the ligand (radionuclide)

to the chelate.• The second is attaching that ligand-chelate

complex to the biomolecule.• This can be direct labelling, use of prosthetic

groups, or click chemistry in particular

Page 40: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

PET

• Direct Labelling• Prosthetic groups• Al-F NOTA• Click chemistry

Page 41: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Direct Labelling

Page 42: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Direct Labelling

Page 43: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Direct Labelling

Page 44: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Direct Labelling

Page 45: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Prosthetic Group Activation

Page 46: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Prosthetic Group Activation

Page 47: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Prosthetic Group Activation

Page 48: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Issues with Prosthetic Groups

• Multiple steps • Long synthesis time • Require HPLC purification• Hard to automate

Page 49: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Advantages of Metal Chelates

• Single step• Rapid• Reaction in aqueous solution• Little substrate required• Minimal purification• Kit formulation

Page 50: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click Chemistry

Page 51: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

PET Chelators

• NOTA

Page 52: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

PET Chelators

• DOTA

Page 53: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

PET Chelators

• TETA

Page 54: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click ChemistryA desirable click chemistry reaction would:•be modular•be wide in scope•give very high chemical yields•generate only benign by-products •be stereospecific•be physiologically stable•have simple reaction conditions•use readily available materials and reagents•use no or a benign solvent•Provide simple product isolation.

Page 55: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Direct Labelling

Page 56: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click Chemistry

Page 57: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click Chemistry

• 4-[18F] fluorobenzoic acid (FBA)

Page 58: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click Chemistry - Selectivity

Page 59: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Click Chemistry - Modularity

Page 60: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

.4.Apply knowledge to prototype model.

Somatostatin Receptor Imaging and Therapy

Theronostic Pairs

Page 61: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Somatostatin Dota Chelator

Page 62: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Affinities

1

2

3

4

5

SSR

Lanreotide Octreotide (NOC) Octreotate

Courtesy John Buscombe formerly Royal Free Hosp London

Page 63: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Title

• Content

Courtesy John Buscombe formerly Royal Free Hosp London

Page 64: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Ga-68

Courtesy John Buscombe formerly Royal Free Hosp London

Positive PET and negative 111In

Page 65: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

In-111 OctGa-68 PET

Similar Lesions

Courtesy John Buscombe formerly Royal Free Hosp London

Page 66: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Ga-68 PET/CT more lesions than In-111 Oct

Ga-68 PET

In-111 Oct

Courtesy John Buscombe formerly Royal Free Hosp London

Page 67: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Title

• Content

Baum et al 2012 Theronostics

Page 68: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Title

• Content

Baum et al 2012 Theronostics

Page 69: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

90Y octreotate therapy

• Content

Baum et al 2012 Theronostics

Page 70: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

Title

• Content

Page 71: FACULTY OF SCIENCE Prof Geoff Currie, BPharm, MMedRadSc, MAppMngt, MBA, PhD Faculty of Science, Charles Sturt University Faculty of Medicine and Health

FACULTY OF SCIENCE

.5.Questions.